The Norwegian Agency for Development Cooperation (Norad) has commissioned the Norwegian Institute of Public Health (NIPH) to conduct a review of the Norwegian Ministry of Foreign Affairs [...]
• The clinical trial will be conducted by South African Tuberculosis Vaccine Initiative (SATVI). • BIOFABRI, biotechnology company focusing on human health vaccines, will sponsor the Phase [...]
Enrolment of the first infant in VPM 1002, a phase 2 clinical trial of a new vaccine to prevent tuberculosis (TB) has successfully started at the South African Tuberculosis Vaccine Initiative [...]
Enrollment of the first infant in a phase 2 clinical trial of a new vaccine to prevent tuberculosis (TB) has successfully started. VPM1002, the most advanced new TB vaccine in clinical [...]
Today the 2014 annual report of the TuBerculosis Vaccine Initiative (TBVI) was released. In this report, you are being updated on the TBVI strategy and we elaborate on the services we offer to [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: +31 320 277 550
